文献速递湿疹皮炎与荨麻疹

小于12岁中重度特应性皮炎系统治疗的2年真实世界结果

Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis.
PubMed 文献 · J Am Acad Dermatol · 2024-10-09

PEDIatric STudy in Atopic Dermatitis(NCT03687359)是一项真实世界前瞻性观察性10年研究,纳入12岁以下控制不佳的中重度特应性皮炎患儿,报告2年中期结果。度普利尤单抗、甲氨蝶呤和环孢素的中位治疗时长分别为8.1、13.0和10.7个月;度普利尤单抗组在EASI、受累体表面积、瘙痒和POEM等方面的组内改善数值上大于甲氨蝶呤和环孢素,且停药和不良事件更少。

要点

  • 度普利尤单抗在多项疗效指标上的组内改善数值大于甲氨蝶呤和环孢素。
  • 度普利尤单抗停药比例(8.3%)低于甲氨蝶呤(28.9%)和环孢素(43.0%)。
  • 该研究未随机、无安慰剂、未规定剂量,结果需谨慎解读。

核心结论

  • 在12岁以下中重度特应性皮炎患儿中,度普利尤单抗的疗效数值和依从性优于环孢素或甲氨蝶呤。

研究设计与样本

  • PEDIatric STudy in Atopic Dermatitis(NCT03687359)为真实世界、前瞻性、观察性10年研究。
  • 研究对象为小于12岁、控制不佳的中重度特应性皮炎患儿,报告2年中期结果。
  • 度普利尤单抗n=144,甲氨蝶呤n=114,环孢素n=121。

主要发现

  • 度普利尤单抗、甲氨蝶呤和环孢素的中位治疗时长分别为8.1、13.0和10.7个月。
  • EASI组内改善:度普利尤单抗-12.4,甲氨蝶呤-5.7,环孢素-3.3(均P<.05)。
  • 受累体表面积组内改善:度普利尤单抗-19.9%,甲氨蝶呤-11.8%,环孢素-8.8%(均P<.05)。
  • 6岁及以上夜间瘙痒组内改善:度普利尤单抗-2.1,甲氨蝶呤-0.4,环孢素+0.1;日间瘙痒:-1.5、+0.1、+0.2。
  • 小于6岁瘙痒/抓挠组内改善:度普利尤单抗-3.6,甲氨蝶呤-1.4,环孢素-0.2;POEM:-7.0、-4.7、-1.5。

关键数值与推荐

  • 停药比例:度普利尤单抗8.3%,甲氨蝶呤28.9%,环孢素43.0%。
  • 不良事件比例:度普利尤单抗18.1%,甲氨蝶呤29.8%,环孢素31.4%。

临床怎么用

  • 对于12岁以下中重度特应性皮炎患儿,度普利尤单抗在真实世界中显示出较好的疗效数值和依从性。
  • 甲氨蝶呤和环孢素仍在使用,但停药比例和不良事件比例较高,需加强监测。

局限性

  • 无随机化、无安慰剂、未规定具体剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The arrival of biologics and small-molecule therapies (eg Janus kinase inhibitors) changed atopic dermatitis treatment, but older systemic treatments continue to be prescribed. OBJECTIVE: To provide real-world effectiveness, safety, and adherence data for dupilumab, cyclosporine, and methotrexate. METHODS: PEDIatric STudy in Atopic Dermatitis (NCT03687359) is a real-world, prospective, observational, 10-year study of children (<12 years) with inadequately controlled moderate-to-severe atopic dermatitis. We report 2-year interim results. RESULTS: Median treatment durations were 8.1, 13.0, and 10.7 months for dupilumab (n = 144), methotrexate (n = 114), and cyclosporine (n = 121), respectively. Dupilumab had numerically greater within-group improvements than methotrexate and cyclosporine in Eczema Area and Severity Index (-12.4∗ vs -5.7∗ and -3.3); body surface area affected (-19.9%∗ vs -11.8%∗ and -8.8%∗); itching (night-time: -2.1∗ vs -0.4 and + 0.1; daytime: -1.5∗ vs +0.1 and + 0.2; ≥6 years); itching/scratching (-3.6∗ vs -1.4∗ and -0.2; <6 years); and Patient-Oriented Eczema Measure (-7.0∗ vs -4.7∗ and -1.5) (∗P < .05 within-group improvements from baseline). Dupilumab had less discontinuations (8.3% vs 28.9% and 43.0%) and adverse event(s) (18.1% vs 29.8% and 31.4%). LIMITATIONS: No randomization, placebo, or specified dosages. CONCLUSION: Dupilumab was associated with numerically greater outcomes and higher adherence than cyclosporine or methotrexate.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Paller AS, de Bruin-Weller M, Marcoux D, et al. Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis. J Am Acad Dermatol. 2024. PMID: 39389429. doi:10.1016/j.jaad.2024.09.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。